Besides, the frequency of EMOE+CD8+ T cells in post-treatment samples was higher in responding patients after relatlimab and nivolumab treatment, achieving a 70% pathologic remission rate in patients with resectable stage III or IV hypermetastatic melanoma with a favorable safety profile (53). This evidence concerns the gene CD8A and melanoma.